Role of Vitamin D Supplementation in Hypertension

Goel, Rajesh Kumar; Lal, Harbans

doi:10.1007/s12291-010-0092-0

Cited by 31 publications

(28 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…They revealed that supplemental vitamin D3 and calcium have no effect on blood pressure (13). As well as, a clinical trial, showed supplemental vitamin D3 with antihypertensive regimen have stronger therapeutic effect than antihypertensive drug alone (14). Despite all the facts, we observed no association between supplemental calcium and vitamin D3 and blood pressure.…”

Section: Discussioncontrasting

confidence: 48%

Impact of supplemental vitamin D3 and calcium on hypercholesterolemia

2018

View full text Add to dashboard Cite

Aim:In the present crossover study, we aimed to assess if calcium and vitamin D can help statins for treatment of hypercholesterolemia. Method: This crossover study was conducted on 60 participants with newly diagnosed hypercholesterolemia. In first phase of study, all patients were administered one 20-mg tablet of atorvastatin every bedtime for sex weeks. Thereafter, in the second phase, all participants received 400 IU vitamin D3 and 1000 mg calcium in addition to previous regimen. After each phase, Lipid profile was evaluated for all participants. Results: 60 individuals including 26 men (43.3%) and 34 women (56.7%) participated in this study. There was significant decrease in triglyceride, total cholesterol and LDL after six weeks treatment with atorvastatin. However, HDL showed no significant change. When blood lipid values after statin therapy was compared to the values after treatment with atorvastatin plus supplemental calcium and vitamin D3, none showed statistically significant change. BMI was found to decrease significantly in both phase of treatment, but blood pressure showed no change. Conclusion: In summary, we observed that supplemental calcium and vitamin D3 have no significant impact on lipid profile and blood pressure. However, we found that supplemental calcium and vitamin D3 decreased BMI, but more studies are in need to support our results.

show abstract

Section: Discussioncontrasting

confidence: 48%

Impact of supplemental vitamin D3 and calcium on hypercholesterolemia

2018

View full text Add to dashboard Cite

show abstract

“…Supplementation of vitamin D resulted in reduction of 0.2 mmHg of systolic BP for each increase of 1 ng/mL of vitamin D over three months (p = 0.02) [26]. Similarly supplementation of vitamin D (33,000 IU of vitamin D 3 , after every 2 weeks, for 3 months) in 100 hypertensive patients demonstrated significant decrease in systolic blood pressure [27]. In a meta analysis by Wu et al [28], oral supplementation of vitamin D was reported associated with significant reduction in systolic but not diastolic blood pressure [28].…”

Section: Intervention Studiesmentioning

confidence: 90%

Interplay of vitamin D and metabolic syndrome: A review

Prasad

Kochhar

2016

Diabetes & Metabolic Syndrome: Clinical Research & Revi

View full text Add to dashboard Cite

“…Although the evidence from animal studies clearly links vitamin D to blood pressure, vitamin D supplementation studies on hypertension in humans yielded mixed results. Vitamin D 3 (33000 IU) administration for every 2-weeks for six months reduced systolic blood pressure significantly [63]. A large meta-analysis of 81 studies by Mirhosseini et al [64] reported that vitamin D improved blood pressure, dyslipidemia, and hypertension.…”

Section: Discussionmentioning

confidence: 99%

Serum Vitamin D Concentration ≥75 nmol/L Is Related to Decreased Cardiometabolic and Inflammatory Biomarkers, Metabolic Syndrome, and Diabetes; and Increased Cardiorespiratory Fitness in US Adults

2020

View full text Add to dashboard Cite

A serum vitamin D [25-hydroxyvitamin D, 25(OH)D] concentration of ≥75 nmol/L is recommended for optimal health. We investigated the relationship between serum 25(OH)D and metabolic syndrome (MetS), diabetes, cardiometabolic biomarkers, and cardiorespiratory fitness (CRF) in US adults using clinical cut points recommended by health organizations. Data from USA’s National Health and Nutrition Examination Surveys were used. Prevalences and likelihood of having MetS and diabetes according to clinical cut points for serum 25(OH)D (<30 nmol/L, 30-<50 nmol/L, 50-<75 nmo/L, and ≥75 nmol/L) were determined with multivariate logistic regression. Relations between serum 25(OH)D and various cardiometabolic biomarkers, CRF, MetS, and diabetes were tested using multivariable adjusted regression. Prevalence of MetS and diabetes were significantly lower in individuals with serum 25(OH)D ≥75 nmol/L (MetS, 21.6%; diabetes, 4.1%) compared to those with 25(OH)D <30 nmol/L (MetS, 45.5%; diabetes, 11.6%) (p < 0.0001). Individuals with serum 25(OH)D ≥75 nmol/L had significantly lower waist circumference (p < 0.0001), C-reactive protein (p = 0.003), glycated hemoglobin (p < 0.0002), fasting triglycerides (p < 0.0001), total homocysteine (p < 0.0001), and insulin resistance (p = 0.0001) and had significantly higher HDL-cholesterol (p < 0.0001) and maximal oxygen uptake (marker for CRF) (p< 0.0009) compared to those with 25(OH)D <30 nmol/L. In conclusion, serum 25(OH)D ≥75 nmol/L is associated with positive indicators related to cardiometabolic diseases in US adults.

show abstract

Role of Vitamin D Supplementation in Hypertension

Cited by 31 publications

References 15 publications

Impact of supplemental vitamin D3 and calcium on hypercholesterolemia

Impact of supplemental vitamin D3 and calcium on hypercholesterolemia

Interplay of vitamin D and metabolic syndrome: A review

Serum Vitamin D Concentration ≥75 nmol/L Is Related to Decreased Cardiometabolic and Inflammatory Biomarkers, Metabolic Syndrome, and Diabetes; and Increased Cardiorespiratory Fitness in US Adults

Contact Info

Product

Resources

About